| Date Checked | 2025-12-21 23:40:41 |
|---|
| Graham Number | (PB)24.67 vs (PE)34.92 |
|---|
| Over / Under Value Percentage | 92.19% vs 50.65% |
|---|
| Dividend Yield | 4.65% |
|---|
| Dividend Date | 2026-02-02 |
|---|
| Symbol | BMY |
|---|
| AssetType | Common Stock |
|---|
| Name | Bristol-Myers Squibb Company |
|---|
| Description | Bristol-Myers Squibb Company (BMY) is a premier biopharmaceutical enterprise headquartered in New York City, renowned for its groundbreaking contributions to therapeutics in oncology, immunology, cardiovascular diseases, and hematology. The company boasts a diverse portfolio of market-leading medications and a promising pipeline that addresses critical unmet medical needs, enhanced by strategic collaborations that bolster its competitive positioning. BMY's unwavering focus on innovation and commitment to rigorous research and development underpin its potential for sustained growth, making it a key player within the evolving biopharmaceutical landscape. |
|---|
| CIK | 14272 |
|---|
| Exchange | NYSE |
|---|
| Currency | USD |
|---|
| Country | USA |
|---|
| Sector | HEALTHCARE |
|---|
| Industry | DRUG MANUFACTURERS - GENERAL |
|---|
| Address | ROUTE 206 & PROVINCE LINE ROAD, PRINCETON, NJ, UNITED STATES, 08543 |
|---|
| OfficialSite | https://www.bms.com |
|---|
| FiscalYearEnd | December |
|---|
| LatestQuarter | 2025-09-30 |
|---|
| MarketCapitalization | 110317453000 |
|---|
| EBITDA | 19217000000 |
|---|
| PERatio | 18.25 |
|---|
| PEGRatio | 2.256 |
|---|
| BookValue | 9.11 |
|---|
| DividendPerShare | 2.48 |
|---|
| EPS | 2.97 |
|---|
| RevenuePerShareTTM | 23.63 |
|---|
| ProfitMargin | 0.126 |
|---|
| OperatingMarginTTM | 0.316 |
|---|
| ReturnOnAssetsTTM | 0.0939 |
|---|
| ReturnOnEquityTTM | 0.338 |
|---|
| RevenueTTM | 48034001000 |
|---|
| GrossProfitTTM | 35135001000 |
|---|
| DilutedEPSTTM | 2.97 |
|---|
| QuarterlyEarningsGrowthYOY | 0.809 |
|---|
| QuarterlyRevenueGrowthYOY | 0.028 |
|---|
| AnalystTargetPrice | 54.5 |
|---|
| AnalystRatingStrongBuy | 3 |
|---|
| AnalystRatingBuy | 3 |
|---|
| AnalystRatingHold | 20 |
|---|
| AnalystRatingSell | 1 |
|---|
| AnalystRatingStrongSell | 0 |
|---|
| TrailingPE | 18.25 |
|---|
| ForwardPE | 8.82 |
|---|
| PriceToSalesRatioTTM | 2.297 |
|---|
| PriceToBookRatio | 5.85 |
|---|
| EVToRevenue | 2.979 |
|---|
| EVToEBITDA | 9.6 |
|---|
| Beta | 0.302 |
|---|
| 52WeekHigh | 61.0 |
|---|
| 52WeekLow | 42.38 |
|---|
| 50DayMovingAverage | 47.42 |
|---|
| 200DayMovingAverage | 48.81 |
|---|
| SharesOutstanding | 2035753000 |
|---|
| SharesFloat | 2032496000 |
|---|
| PercentInsiders | 0.085 |
|---|
| PercentInstitutions | 81.888 |
|---|
| ExDividendDate | 2026-01-02 |
|---|
| naga | 1 |
|---|
| etoro | 1 |
|---|
| dateChecked | 2025-12-21 23:40:41 |
|---|
| fresh | 1 |
|---|